Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology

Abstract Background Familial hypercholesterolaemia (FH) is a hereditary disorder predisposing to premature coronary heart disease (CHD) and is until now mainly diagnosed clinically on the basis of a classical phenotype. Its prevalence varies and is estimated around 1 in 200–500; in patients with est...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2015-07, Vol.241 (1), p.169-175
Main Authors: De Backer, Guy, Besseling, Joost, Chapman, John, Hovingh, G.Kees, Kastelein, John J.P, Kotseva, Kornelia, Ray, Kausik, Reiner, Željko, Wood, David, De Bacquer, Dirk
Format: Article
Language:English
Subjects:
Age Distribution
Age Factors
Aged
Cardiovascular
Comorbidity
Coronary Disease - diagnosis
Coronary Disease - epidemiology
Coronary Disease - genetics
Coronary Disease - therapy
Coronary heart disease
Cross-Sectional Studies
Europe - epidemiology
Familial hypercholesterolaemia
Female
Genetic Predisposition to Disease
Health Surveys
Humans
Hyperlipoproteinemia Type II - diagnosis
Hyperlipoproteinemia Type II - epidemiology
Hyperlipoproteinemia Type II - genetics
Hyperlipoproteinemia Type II - therapy
Life Style
Male
Middle Aged
Phenotype
Prevalence
Risk Factors
Sex Distribution
Sex Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Familial hypercholesterolaemia (FH) is a hereditary disorder predisposing to premature coronary heart disease (CHD) and is until now mainly diagnosed clinically on the basis of a classical phenotype. Its prevalence varies and is estimated around 1 in 200–500; in patients with established CHD the prevalence is less well documented. Methods and results In EUROASPIRE IV data were collected in coronary patients from 24 European countries by means of a standardized interview, bioclinical examination and venous blood sampling. Potential FH was estimated using an adapted version of the Dutch Lipid Clinic Network Criteria. Among the 7044 patients eligible for analysis, the prevalence of potential FH was 8.3%; 7.5% in men and 11.1% in women. The prevalence was inversely related to age with a putative prevalence of 1:5 in those with CHD
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2015.04.809